Markets

Oculis Says Phase 2 ACUITY Biomarker Data Show Privosegtor Lowered NfL, GFAP Versus Placebo In Optic Neuritis, Strengthening Confidence In PIONEER Registrational Program, Exploring Acute MS Relapses

Oct 22, 2026 · 03:31 AM ET· updated 55m ago

Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placeboLower NfL and GFAP levels provide objective, complementary biological

Why It Matters

Oculis tested a medicine called Privosegtor on eye nerve damage. The medicine lowered certain biological markers better than placebo, suggesting it may work.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

OCS7.90

+0.41 (+5.47%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.